Background The incidence of diverticulosis and diverticular disease of the colon, including
diverticulitis, is increasing worldwide, and becoming a significant burden on national health …

Synopsis Rifaximin is a derivative of rifamycin which acts by inhibiting bacterial ribonucleic
acid (RNA) synthesis. It is virtually unabsorbed after oral administration; thus it is used …

The statements produced by the Consensus Conference on Diverticular Disease promoted
by GRIMAD (Gruppo Italiano Malattia Diverticolare, Italian Group on Diverticular Diseases) …

Aliment Pharmacol Ther 2011; 33: 902–910 Summary Background Diverticular disease of
the colon is a common gastrointestinal disease. Although most patients remain …

Disease-specific variations in intestinal microbiome composition have been found for a
number of intestinal disorders, but little is known about diverticulitis. The purpose of this …

Diverticular disease of the colon is the fifth most important gastrointestinal disease in terms
of direct and indirect healthcare costs in western countries. Uncomplicated diverticular …

Background and aims: In a recent open trial we have shown the efficacy of long term
intermittent administration of a poorly absorbable antibiotic (rifaximin) in obtaining …

Background and aims. We examined the efficacy of cyclic long-term administration of
rifaximin, a broad spectrum, poorly absorbable antibiotic, in obtaining symptom relief in a …

Background/Aims. To compare efficacy of combined therapy with rifaximin and mesalazine
versus rifaximin alone in treatment of patients with recurrent diverticulitis in order to evaluate …

BACKGROUND: Evidence supporting appropriate medical therapy to prevent recurrence of
colonic diverticulitis is limited. Our goal was to evaluate the potential of rifaximin given …